Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal Therapy

Art Rastinehad, DO
Published: Thursday, Jun 02, 2016


Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
 
Prostate is the last solid organ malignancy that is diagnosed by randomly sampling the gland, says Rastinehad.
 
A transperineal MR/TRUS fusion biopsy system has been developed that tracks the probe and needles with EM tracking. This technology has potential for application in transperineal focal therapy.
 
The system is FDA cleared for treatment, so oncologists can diagnosis and treat specific areas in the prostate. This may reduce the need for radiation and/or surgery.
 

Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
 
Prostate is the last solid organ malignancy that is diagnosed by randomly sampling the gland, says Rastinehad.
 
A transperineal MR/TRUS fusion biopsy system has been developed that tracks the probe and needles with EM tracking. This technology has potential for application in transperineal focal therapy.
 
The system is FDA cleared for treatment, so oncologists can diagnosis and treat specific areas in the prostate. This may reduce the need for radiation and/or surgery.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x